Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S. Repessé Y, et al. Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. Haematologica. 2019. PMID: 30705098 Free PMC article. No abstract available.
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.
Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S. Dasgupta S, et al. Among authors: repesse y. Blood. 2007 Jan 15;109(2):610-2. doi: 10.1182/blood-2006-05-022756. Epub 2006 Sep 19. Blood. 2007. PMID: 16985172 Free article.
The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S, Repessé Y, Kaveri SV, Dasgupta S. Lacroix-Desmazes S, et al. Among authors: repesse y. Thromb Res. 2008;122 Suppl 2:S3-6. doi: 10.1016/S0049-3848(08)70002-1. Thromb Res. 2008. PMID: 18549909 Review.
A cellular viewpoint of anti-FVIII immune response in hemophilia A.
André S, Meslier Y, Dimitrov JD, Repessé Y, Kaveri SV, Lacroix-Desmazes S, Dasgupta S. André S, et al. Among authors: repesse y. Clin Rev Allergy Immunol. 2009 Oct;37(2):105-13. doi: 10.1007/s12016-009-8117-2. Clin Rev Allergy Immunol. 2009. PMID: 19165635 Review.
Inhibitors of factor VIII in hemophilia.
Lacroix-Desmazes S, Dimitrov JD, Repesse Y. Lacroix-Desmazes S, et al. Among authors: repesse y. N Engl J Med. 2009 Jul 16;361(3):308; author reply 310. doi: 10.1056/NEJMc091067. N Engl J Med. 2009. PMID: 19605840 No abstract available.
Proteolytic antibodies activate factor IX in patients with acquired hemophilia.
Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S. Wootla B, et al. Among authors: repesse y. Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3. Blood. 2011. PMID: 21131590 Free article. Clinical Trial.
60 results